StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) income statement

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$9.95−0.62 (-5.87%)

Close on Nov 20, 2026Market cap $7.94BP/E –Yield –

Summit Therapeutics Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-206.1%

Financial strength

Current ratio
6.96
Debt to equity
–
Debt to assets
–
Cash to current liabilities
404.9%

Valuation

P/E ratio
–
Price to sales
–
Price to book
12.60
Dividend yield
–

See a number that looks wrong?